About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Media Stories

2019 2018 2017 2016 2015

October 2018
26 Oct  Biocon Sep-quarter net profit sees five-fold surge on exceptional income
25 Oct  Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018
19 Oct  CHMP nod for Ogivri Biocon and Mylan expect EC call by end of year
September 2018
24 Sep  They were not comfortable about hiring a woman
21 Sep  Biocon closer to Europe approval of biosimilar Pegfilgrastim
15 Sep  Grit is her secret Formula
August 2018
1 Aug  Biocon targets $200mn revenue from Biosimilars
July 2018
26 July  Biocon posts 47% increase in 1st quarter net profit
5 July  Biocon gets EU GMP clearance for Bangalore facility
June 2018
6 June  U.S. FDA approves Biocon-Mylan’s first biosimilar of cancer drug Neulasta
May 2018
20 May  Biocon bets on R&D, biosimilars business to boost growth in FY19
April 2018
26 Apr  Biocon's profit inches up 2% in fourth quarter
March 2018
28 Mar  Biocon, Mylan get EC nod to market biosimilar insulin glargine
February 2018
6 Feb  Global pharma is moving to biotherapy, and that’s Biocon’s strength: Kiran Mazumdar-Shaw
January 2018
19 Jan  Biocon teams up with Sandoz for next gen biosimilars

 

 

   
 
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved